-
UPDATE: H.C. Wainwright Initiates Coverage on United States Antimony Ahead of Possible North American-Centric Monopoly
Thursday, October 3, 2013 - 12:05pm | 156Read More...In a report published Thursday, H.C. Wainwright & Co. analyst Jeffrey Wright initiated coverage on United States Antimony Corporation (NYSE: UAMY) with a Buy rating and $3.00 price target. In the report, H.C. Wainwright & Co. noted, “UAMY is set up to evolve and grow into a North American...
-
UPDATE: H.C. Wainwright Initiates Coverage on Keryx Biopharmaceuticals on Discounted Revenues, EPS Valuation Methodology
Wednesday, September 25, 2013 - 11:15am | 138Read More...In a report published Wednesday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a Buy rating and $15.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Keryx Biopharmaceuticals with a...
